Clinical InvestigationDoes clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry
Section snippets
Study population
The PALM registry consists of 7938 patients enrolled at 140 outpatient cardiology, endocrinology, and primary care practices across the United States. The design, rationale, inclusion, and exclusion criteria for the PALM registry have been previously published.9 After each site obtained institutional review board approval for participation, all clinicians at participating sites were asked to complete a web-based provider survey. Sites were required to have completed surveys for >80% of
Provider survey results
The PALM Registry collected provider surveys for 774 clinicians treating patients at 51 primary care practices, 82 cardiology practices, and 8 endocrinology practices. Among surveyed clinicians, 574 (74.2%) reported that the 2013 ACC/AHA guidelines primarily guides their lipid management, 137 (17.7%) are primarily guided by the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII), 16 (2.1%) by the American Association of Clinical
Discussion
In this analysis of the PALM registry, we compared clinician responses to hypothetical scenarios with the observed treatment of their patients. We demonstrated that: (1) the majority of cardiologists reported adoption of the 2013 ACC/AHA guidelines and were more likely to adopt than primary care physicians or endocrinologists. (2) Clinician responses to hypothetical scenarios do not always align with observed lipid management decisions. (3) When the risk calculator was utilized, more guideline
Conclusions
Since the release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, there has been variable uptake in implementation of these guidelines, with cardiologists reporting the highest guideline adoption. Despite recommendations, statin therapy remains under-utilized in primary prevention patients with diabetes or with high ASCVD risk. Additional clinician treatment uncertainty remains around the management of patients with
Disclosures
The authors report the following disclosures: Dr. Lowenstern received funding through NIH T-32 training grant #5 T32 HL069749-14. Ms. Li reports no relevant disclosures. Dr. Navar reports research support from Amgen, Sanofi, and Regeneron; consulting fees from Amgen and Sanofi. Dr. Virani reports research support from ADA/AHA/ VA; honorarium from ACC as the Associate Editor for Innovations, ACC.org. Dr. Lee reports employment with Sanofi. Dr. Louie reports employment with Regeneron
Author Contributions
All authors have been involved in the study design, analysis, and manuscript revision. All authors read and approved the final manuscript. Dr Lowenstern is the guarantor who accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.
A Lowenstern: Dr Lowenstern had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Lowenstern
Acknowledgements
We thank Erin Campbell, MS, for her editorial contributions to this article. Ms. Campbell did not receive compensation for her assistance, apart from her employment at the institution where this study was conducted. This study was funded by Sanofi and Regeneron Pharmaceuticals.
References (18)
- et al.
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
J Am Coll Cardiol
(2005) - et al.
Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry
Am Heart J
(2015) - et al.
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary
Endocr Pract
(2012) - et al.
American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Endocr Pract
(2017) - et al.
Provider understanding of the 2013 ACC/AHA cholesterol guideline
J Clin Lipidol
(2016) - et al.
Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations
Lancet
(1993) - et al.
Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force
JAMA
(2016) - et al.
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
JAMA
(2005) - et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
N Engl J Med
(2005)
Cited by (14)
Trends of Lipid Concentrations, Awareness, Evaluation, and Treatment in Severe Dyslipidemia in US Adults
2024, Mayo Clinic ProceedingsTrends and determinants of prevalence, awareness, treatment and control of dyslipidaemia in canton of Geneva, 2005–2019: Potent statins are underused
2023, International Journal of Cardiology: Cardiovascular Risk and PreventionThe Attitudes of Physicians Toward Guideline Recommendations for the Management of Dyslipidemia in Clinical Practice - The VIPFARMA ISCP Project
2023, Current Problems in CardiologyCitation Excerpt :Previously published studies reinforce this perspective. The PALM Registry collected provider surveys for 774 clinicians treating patients at 51 primary care practices, 82 cardiology practices, and 8 endocrinology practices.19 In a hypothetical scenario involving secondary prevention, in patients with persistently high LDL-C despite treatment adherence with high-intensity statin therapy, 26.9% of providers chose to change the statin, 51.4% chose to add a non-statin lipid-lowering agent (ezetimibe, fibrate, fish oil, or bile acid sequestrant), and 18.0% of clinicians chose to not change treatment.
High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.
2022, Journal of the American College of CardiologyCitation Excerpt :The lack of medication changes together with evidence that >70% of this cohort’s LDL-C levels were not to target supports the presence of significant clinician inertia.23 Some of the contributing factors may include a lack of knowledge of guidelines and the role of high-intensity statins,17 discordance between guideline knowledge and physician prescribing habits,24 a lack of confidence navigating perceived statin intolerance,25 and contrarian beliefs about the role of statins.26 Given that prior studies have previously documented evidence of widespread practice- and provider-level variation in the use of high-intensity statins,27,28 multifaceted interventions harnessing educational outreach as well as audit and feedback are likely to be needed to overcome patient-, clinician-, and system-level barriers.
An exploratory survey on the awareness and usage of clinical practice guidelines among clinical pharmacists
2021, Exploratory Research in Clinical and Social PharmacyBeliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry: Lipid Treatment in PALM Patients with Diabetes
2020, American Heart JournalCitation Excerpt :Further, guideline-recommended treatment with a statin was based on definitions from the 2013 ACC/AHA guideline. While 74.2% of clinicians from the PALM registry reported use of the ACC/AHA guideline as their primary tool for lipid management,19 use of other guideline recommendations may have contributed to some of the treatment results we observed. Additionally, there are minor differences in determining high intensity statin treatment for primary prevention patients with DM between the ACC/AHA 2013 and 2018 guidelines.
Sources of funding: This study was funded by Sanofi and Regeneron Pharmaceuticals.
Christopher P. Cannon, MD served as guest editor for this article.
- 1
Dr Lowenstern received funding through NIH T-32 training grant #5 T32 HL069749–14.
- 2
Ms Li reports no relevant disclosures.
- 3
Dr Navar reports research support from Amgen, Sanofi, and Regeneron; consulting fees from Amgen and Sanofi.
- 4
Dr Virani reports research support from ADA/AHA/ VA; honorarium from ACC as the Associate Editor for Innovations, ACC.org.
- 5
Dr Lee reports employment with Sanofi.
- 6
Dr Louie reports employment with Regeneron Pharmaceuticals, Inc.; ownership interest in Regeneron Pharmaceuticals, Inc.
- 7
Dr Peterson reports research support from Eli Lilly, Janssen, Merck, Consulting from AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, Janssen, Merck, and Sanofi Aventis;
- 8
Dr Wang reports research support from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Glaxo SmithKline, Regeneron, Sanofi; consultant/advisory/education from Bristol Myers Squibb, Astra Zeneca, Eli Lilly, Premier, Inc.